Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruibin Huang

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Journal of Translational Internal Medicine|December 22, 2023
Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trialHu Zhou, Shouqing Han, Jie Jin, et al.
Annals of Hematology|June 6, 2024
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Research and Practice in Thrombosis and Haemostasis|December 10, 2025
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension studyHeng Mei, Xiaofan Liu, Yan Li, et al.
The Lancet. Haematology|June 17, 2024
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 studyYu Hu, Xiaofan Liu, Hu Zhou, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Journal of Translational Internal Medicine|December 22, 2023
Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trialHu Zhou, Shouqing Han, Jie Jin, et al.
Annals of Hematology|June 6, 2024
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Research and Practice in Thrombosis and Haemostasis|December 10, 2025
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension studyHeng Mei, Xiaofan Liu, Yan Li, et al.
The Lancet. Haematology|June 17, 2024
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 studyYu Hu, Xiaofan Liu, Hu Zhou, et al.
Pageof 9